Cosentyx Psoriasis Drug an Effective Treatment …

Curated by

 

The one-year trial results confirmed that Cosentyx has long term efficacy in the treatment of psoriatic arthritis and psoriasis. Cosentyx got the approval from U.S. Food and Drug Administration for the treatment of psoriasis, in January 2015. But the Swiss drugmaker is keen to launch the drug for other related diseases, too. According to recent trial results published in The Lancet, showed promising efficacy of the injectable drug Cosentyx, produced by Novartis.

 

 

  • Patients were administered with either 300mg or 150mg dose, as per the condition.
  • If left untreated, complications like dysfunctional joints, heart-valve complications and eye, bowel or lung irritations may occur, triggering a serious condition.
  • First from the class of IL-17A inhibitors, Cosentyx treat by targeting the protein which is linked to inflammation.

 

Article Categories:
Health

Leave a Comment

Your email address will not be published. Required fields are marked *


Categories:

Today we’re announcing that after two years of helping people discover and share great news via this website we will be shutting down this service on June 30.

 

We would like to thank our millions of readers who inspired us with positive feedback and liberal sharing of ideas to help bring the best content to light and keep everybody informed about what is current and important.

 

We are working hard to give the new site a 'lift' which will bring you an even better product that will give you exclusive access to socially-vetted, high-quality news. The new product will give great content the engagement and social reach it deserves. It will also help creators to get trusted feedback about their content to truly understand what their audience is passionate about.

Something cool is coming soon! Be the first to know!

 

Enter your name and email and we’ll keep you in the loop:

Today we’re announcing that after two years of helping people discover and share great news via this website we will be shutting down this service on June 30.

 

We would like to thank our millions of readers who inspired us with positive feedback and liberal sharing of ideas to help bring the best content to light and keep everybody informed about what is current and important.

 

We are working hard to give the new site a 'lift' which will bring you an even better product that will give you exclusive access to socially-vetted, high-quality news. The new product will give great content the engagement and social reach it deserves. It will also help creators to get trusted feedback about their content to truly understand what their audience is passionate about.

Something cool is coming soon! Be the first to know!

 

Enter your name and email and we’ll keep you in the loop: